Keyword Search Year None20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001 06/06/23 Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations 06/01/23 Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc 05/31/23 Alkermes to Participate in Two Upcoming Investor Conferences 05/25/23 Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value 05/16/23 Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences 05/09/23 Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 05/08/23 Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process 04/26/23 Alkermes plc Reports First Quarter 2023 Financial Results 04/25/23 Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration 04/19/23 Alkermes to Report First Quarter Financial Results on April 26, 2023 04/19/23 Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer 04/18/23 Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business 03/23/23 Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness 03/15/23 Alkermes to Participate in the Stifel 2023 CNS Days 02/16/23 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023 02/09/23 Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 01/17/23 Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
06/06/23 Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
06/01/23 Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
05/25/23 Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value
05/09/23 Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
05/08/23 Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process
04/19/23 Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer
04/18/23 Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business
03/23/23 Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness
02/16/23 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023
01/17/23 Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
